Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263860 | 0.82 | ALDH1A1 (0.48) | TSHRTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL15604713 | 0.82 | ALDH1A1 (0.48) | TSHRTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL15604714 | 0.82 | TRPA1 (0.48) | TSHRTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL131849 | 0.81 | — | — | |
| SCHEMBL95982 | 0.79 | TSHR (1.00) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| SCHEMBL17378039 | 0.79 | ALDH1A1 (0.44) | TSHRTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL16939931 | 0.77 | TRPA1 (0.42) | TSHRTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL15928853 | 0.77 | TRPA1 (0.42) | TSHRTRPA1ALDH1A1CYP3A4HPGD | |
| Ammonia Solution, Strong SCHEMBL8958644 | 0.76 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL10457214 | 0.76 | TSHR (0.93) | TSHRLMNAKMT2AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009156466-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CTG PHARMA S.R.L. (IT) | 2009-12-30 | — | — | WO | claimed |
| WO-2009109501-A2 | OCULAR PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2009-09-11 | — | — | WO | claimed |
| CN-118262766-A | Power supply circuit and power supply method thereof | 长江存储科技有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024134235-A1 | TREATMENT OF MYELOPEROXIDASE-POSITIVE ANCA-ASSOCIATED VASCULITIS WITH H2S RELEASING COMPOUNDS | DEBRECENI EGYETEM (HU) | 2024-06-27 | — | — | WO | disclosed |
| CN-115073439-B | Pyrimidine compound and medical application thereof | 徐州医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-115073439-A | Pyrimidine compound and medical application thereof | 徐州医科大学 | 2022-09-20 | — | — | CN | disclosed |
| US-9242009-B2 | Compositions and methods to treat neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150209438-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2015-07-30 | — | — | US | disclosed |
| WO-2009156466-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CTG PHARMA S.R.L. (IT) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009109501-A2 | OCULAR PHARMACEUTICAL COMPOSITIONS | CTG PHARMA S.R.L. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209438-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | PSEN2, SNCA, PSEN1 | TSHR 4818/4885TRPA1 3595/4885ALDH1A1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.